TriangleHEALTH PROFESSIONAL · SOURCE READING
Tazemetostat
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Tazemetostat is an inhibitor of EZH2, a histone methyltransferase essential to the formation of lymph node germinal centers, especially with activating variants of EZH2.
Evidence (tazemetostat):
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
Source links and citations
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
Treatment with tazemetostat resulted in an objective response rate of 69% (95% CI, 53%–82%) for patients with activating EZH2 variants versus 35% (95% CI, 23%–49%) for patients with wild-type EZH2.[24]
Source links and citations
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
With a median follow-up of 22 months, the median PFS was 13.8 months (95% CI, 10.7–22.0) for patients with activating EZH2 variants and 11.1 months (95% CI, 3.7–14.6) for patients with wild-type EZH2.[24][Level of evidence C3]
Source links and citations
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
Grade 3 or 4 treatment-related adverse events occurred in 4% of patients.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice